STAT+: Pharmalittle: We’re reading about a discontinued cancer drug, a Novo security breach, and more

<iframe
  src="https://statesidedaily.com/embed/cluster/8f1d7c11d342c30ce500d0cb36f1e9947c909cb3"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Pharmalittle: We&#8217;re reading about a discontinued cancer drug, a Novo security breach, and more"></iframe>